Arbutus Biopharma Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ABUS | 2137.HK | ADMA | ASMB | CLYM | AAPG | |
|---|---|---|---|---|---|---|
| Market cap | 622.30M | 739.58M | 2.35B | 404.57M | 535.88M | 1.41B |
| P/E (TTM) | 5.1 | — | 15.0 | 19.1 | — | — |
| Forward P/E | -24.6 | -2.0 | 11.1 | -7.7 | -9.3 | -23.3 |
| Price/book | 3.1 | 0.3 | 5.2 | 1.3 | 2.2 | 16.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −15.84% | −44.59% | −27.72% | −37.96% | +407.81% | −59.04% |
| Today | +4.64% | 0.00% | −5.67% | −0.25% | −4.31% | +11.75% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ABUS news ›EQT, Norges Bank, Ardian Said to Drop Out of EUR10 Billion Bid for Acciona Energía
Swedish private equity giant EQT , Norway's Norges Bank, and French investment firm Ardian have dropped their binding offers for Acciona Energía , Spanish digital newspaper El Confidencial... Investment Management & Fund Operators EQT,…
FDA lifts clinical hold on Arbutus Biopharma AB-101 IND application
Arbutus Biopharma (ABUS) announced that the company was notified by the FDA that the clinical hold on the investigational new drug, or IND, appl... FDA lifts clinical hold on Arbutus Biopharma AB-101 IND application Arbutus Biopharma…
Arbutus Biopharma commences $230M modified Dutch Auction tender offer
Arbutus Biopharma (ABUS) announced the commencement of a modified Dutch Auction tender offer to purchase for cancellation up to $230M in value o... Arbutus Biopharma commences $230M modified Dutch Auction tender offer Arbutus Biopharma…
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage b... Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer…
Prelude Therapeutics (NASDAQ:PRLD) & Arbutus Biopharma (NASDAQ:ABUS) Head-To-Head Comparison
Posted by Defense World Staff on Oct 19th, 2026 Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
Evaxion A/S (NASDAQ:EVAX) vs. Arbutus Biopharma (NASDAQ:ABUS) Head-To-Head Survey
Posted by Sarita Garza on Oct 16th, 2026 Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and Evaxion A/S (NASDAQ:EVAX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the…
Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial Comparison
Posted by Michael Walen on Oct 12th, 2026 Immunome (NASDAQ:IMNM – Get Free Report) and Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
Arbutus Biopharma is a Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Click for more on ABUS stock. - Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com4
- marketscreener.com3
- themarketsdaily.com2
- defenseworld.net1
- mugglehead.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.